BioScience Health Innovations annual cash and equivalents
2020
2021
2022
2022
2023
2024
2025
BioScience Health Innovations Cash & Equivalents Growth & History (BHIC)
BioScience Health Innovations's cash and equivalents was $661,925 for fiscal 2025.
View full BioScience Health Innovations company overviewBioScience Health Innovations annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $661,925 | −$592 | −0.09% |
| 2024 | 2024-12-31 | $662,517 | $643,279 | +3343.79% |
| 2023 | 2023-12-31 | $19,238 | $7,669 | +66.29% |
| 2022 · Dec 31 | 2022-12-31 | $11,569 | — | — |
| 2022 · Aug 31 | 2022-08-31 | $16,253 | $14,218 | +698.67% |
| 2021 | 2021-08-31 | $2,035 | −$18,594 | −90.14% |
| 2020 | 2020-08-31 | $20,629 | — | — |
BioScience Health Innovations quarterly cash and equivalents
As of Aug 31, 2019
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q4.22
Q1.23
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $712,378 | −$587,029 | −45.18% |
| Q1 2026 | 2026-03-31 | $1.1M | $116,663 | +11.34% |
| Q4 2025 | 2025-12-31 | $661,925 | −$592 | −0.09% |
| Q3 2025 | 2025-09-30 | $1.1M | $806,203 | +241.94% |
| Q2 2025 | 2025-06-30 | $1.3M | $1.2M | +802.86% |
| Q1 2025 | 2025-03-31 | $1.0M | $935,407 | +1006.52% |
| Q4 2024 | 2024-12-31 | $662,517 | $643,279 | +3343.79% |
| Q3 2024 | 2024-09-30 | $333,220 | $291,232 | +693.61% |
| Q2 2024 | 2024-06-30 | $143,922 | $113,605 | +374.72% |
| Q1 2024 | 2024-03-31 | $92,935 | $83,471 | +881.98% |
| Q4 2023 | 2023-12-31 | $19,238 | $7,669 | +66.29% |
| Q3 2023 | 2023-09-30 | $41,988 | — | — |
| Q2 2023 | 2023-06-30 | $30,317 | — | — |
| Q1 2023 · Mar 31 | 2023-03-31 | $9,464 | — | — |
| Q1 2023 · Feb 28 | 2023-02-28 | $8,793 | −$62,314 | −87.63% |
| Q4 2022 · Dec 31 | 2022-12-31 | $11,569 | — | — |
| Q1 2023 · Nov 30 | 2022-11-30 | $28,343 | −$67,791 | −70.52% |
| Q4 2022 · Aug 31 | 2022-08-31 | $16,253 | $14,218 | +698.67% |
| Q3 2022 | 2022-05-31 | $24,456 | $24,082 | +6439.04% |
| Q2 2022 | 2022-02-28 | $71,107 | $68,724 | +2883.93% |
| Q1 2022 | 2021-11-30 | $96,134 | $76,083 | +379.45% |
| Q4 2021 | 2021-08-31 | $2,035 | −$18,594 | −90.14% |
| Q3 2021 | 2021-05-31 | $374 | −$22,500 | −98.36% |
| Q2 2021 | 2021-02-28 | $2,383 | −$241 | −9.18% |
| Q1 2021 | 2020-11-30 | $20,051 | $20,051 | — |
| Q4 2020 | 2020-08-31 | $20,629 | $20,629 | — |
| Q3 2020 | 2020-05-31 | $22,874 | — | — |
| Q2 2020 | 2020-02-29 | $2,624 | — | — |
| Q1 2020 | 2019-11-30 | $0 | — | — |
| As of Aug 31, 2019 | 2019-08-31 | $0 | — | — |
BioScience Health Innovations cash and equivalents trends
Between the periods ended 2020-08-31 and 2025-12-31, BioScience Health Innovations's cash and equivalents increased from $20,629 to $661,925, a change of $641,296. The latest reported quarter, Q2 2026, shows $712,378.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioScience Health Innovations source filings ↗